A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

  • STATUS
    Recruiting
  • End date
    May 29, 2026
  • participants needed
    5000
  • sponsor
    Novartis Pharmaceuticals
Updated on 8 September 2021
Investigator
Novartis Pharmaceuticals
Primary Contact
Alamance Regional Medical Cancer Center (0.0 mi away) Contact
+362 other location

Summary

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Details
Condition Early Breast Cancer
Treatment Ribociclib, Endocrine Therapy
Clinical Study IdentifierNCT03701334
SponsorNovartis Pharmaceuticals
Last Modified on8 September 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note